Subclonal landscape of cancer drives resistance to immune therapy

Friedberg, 2003, DNA damage and repair, Nature, 421, 436, 10.1038/nature01408 Chatterjee, 2017, Mechanisms of DNA damage, repair, and mutagenesis, Environ Mol Mutagen, 58, 235, 10.1002/em.22087 Alexandrov, 2013, Deciphering signatures of mutational processes operative in human cancer, Cell Rep, 3, 246, 10.1016/j.celrep.2012.12.008 Nowell, 1976, The clonal evolution of tumor cell populations, Science, 194, 23, 10.1126/science.959840 Prindle, 2010, The mutator phenotype in cancer: molecular mechanisms and targeting strategies, Curr Drug Targets, 11, 1296, 10.2174/1389450111007011296 Greaves, 2012, Clonal evolution in cancer, Nature, 481, 306, 10.1038/nature10762 Yan, 2011, Targeted cancer therapies, Chin J Cancer, 30, 1, 10.5732/cjc.010.10553 Falzone, 2018, Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium, Front Pharmacol, 9, 1300, 10.3389/fphar.2018.01300 Cumming, 2001, Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1, Nat Med, 7, 814, 10.1038/89937 Manolitsas, 1997, No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer, Br J Cancer, 75, 1398, 10.1038/bjc.1997.238 Michael, 2005, Tumoral drug metabolism: overview and its implications for cancer therapy, J Clin Oncol, 23, 205, 10.1200/JCO.2005.02.120 Zhang, 2016, The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis, Oncotarget, 7, 78985, 10.18632/oncotarget.12587 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Dancey, 2003, Issues and progress with protein kinase inhibitors for cancer treatment, Nat Rev Drug Discov, 2, 296, 10.1038/nrd1066 Cheng, 2014, Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives, Onco Targets Ther, 7, 1689, 10.2147/OTT.S66502 Stewart, 2015, Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review, Transl Lung Cancer Res, 4, 67 Kohsaka, 2019, Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing, Future Oncol, 15, 637, 10.2217/fon-2018-0736 Ma, 2011, T790M and acquired resistance of EGFR TKI: a literature review of clinical reports, J Thorac Dis, 3, 10 Soria, 2018, Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137 Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792 Fife, 2011, The role of the PD-1 pathway in autoimmunity and peripheral tolerance, Ann N Y Acad Sci, 1217, 45, 10.1111/j.1749-6632.2010.05919.x Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Buchbinder, 2016, CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition, Am J Clin Oncol, 39, 98, 10.1097/COC.0000000000000239 Fife, 2008, Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways, Immunol Rev, 224, 166, 10.1111/j.1600-065X.2008.00662.x Krummel, 1995, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J Exp Med, 182, 459, 10.1084/jem.182.2.459 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Lipson, 2011, Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma, Clin Cancer Res, 17, 6958, 10.1158/1078-0432.CCR-11-1595 Hodi, 2016, Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial, Lancet Oncol, 17, 1558, 10.1016/S1470-2045(16)30366-7 Brady, 2017, Combating subclonal evolution of resistant cancer phenotypes, Nat Commun, 8, 1231, 10.1038/s41467-017-01174-3 Schmitt, 2016, The influence of subclonal resistance mutations on targeted cancer therapy, Nat Rev Clin Oncol, 13, 335, 10.1038/nrclinonc.2015.175 Lennerz, 2005, The response of autologous T cells to a human melanoma is dominated by mutated neoantigens, Proc Natl Acad Sci U S A., 102, 16013, 10.1073/pnas.0500090102 Robbins, 2013, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat Med, 19, 747, 10.1038/nm.3161 Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9 Marusyk, 2012, Intra-tumour heterogeneity: a looking glass for cancer?, Nat Rev Cancer, 12, 323, 10.1038/nrc3261 McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490 Callahan, 2008, Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer, Clin Cancer Res, 14, 7667, 10.1158/1078-0432.CCR-08-0479 Forero, 2016, Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes, Cancer Immunol Res, 4, 390, 10.1158/2326-6066.CIR-15-0243 Morand, 2020, BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target, JNCI Cancer Spectrum, 4, 10.1093/jncics/pkaa077 Chan, 2019, IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion, J Clin Invest, 129, 3324, 10.1172/JCI126022 Zaretsky, 2016, Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma, N Engl J Med, 375, 819, 10.1056/NEJMoa1604958 Marabelle, 2017, JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy, Cancer Discov, 7, 128, 10.1158/2159-8290.CD-16-1439 Hewitt, 2003, The MHC class I antigen presentation pathway: strategies for viral immune evasion, Immunology, 110, 163, 10.1046/j.1365-2567.2003.01738.x Cornel, 2020, MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy, Cancers (Basel), 12, 10.3390/cancers12071760 Morrison, 2018, Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells, BMC Cancer, 18, 469, 10.1186/s12885-018-4389-3 York, 2002, The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues, Nat Immunol, 3, 1177, 10.1038/ni860 Mehta, 2009, Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma, Genes Chromosomes Cancer, 48, 410, 10.1002/gcc.20648 Wang, 2013, p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1, Nat Commun, 4, 2359, 10.1038/ncomms3359 Olivier, 2010, TP53 mutations in human cancers: origins, consequences, and clinical use, Cold Spring Harb Perspect Biol, 2, 10.1101/cshperspect.a001008 Nakayama, 2020, Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties, Nat Commun, 11, 2333, 10.1038/s41467-020-16245-1 Rossi, 2014, Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, 123, 2139, 10.1182/blood-2013-11-539726 Johnson, 2018, Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement, JCI Insight, 3, 10.1172/jci.insight.120360 Ascierto, 2017, Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy, J Clin Oncol, 35 Wolf, 2019, UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma, Cell, 179, 219, 10.1016/j.cell.2019.08.032 Gejman, 2018, Rejection of immunogenic tumor clones is limited by clonal fraction, Elife, 7, 10.7554/eLife.41090 Reuben, 2017, TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence, Cancer Discov, 7, 1088, 10.1158/2159-8290.CD-17-0256 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Cha, 2014, Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients, Sci Transl Med, 6, 238ra270, 10.1126/scitranslmed.3008211 Kwa, 2018, Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here, Cancer, 124, 2086, 10.1002/cncr.31272 Cortes, 2020, Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, Lancet, 396, 1817, 10.1016/S0140-6736(20)32531-9 Patel, 2015, PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy, Mol Cancer Ther, 14, 847, 10.1158/1535-7163.MCT-14-0983 Ding, 2012, Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing, Nature, 481, 506, 10.1038/nature10738 Johnson, 2014, Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma, Science, 343, 189, 10.1126/science.1239947 Landau, 2013, Evolution and impact of subclonal mutations in chronic lymphocytic leukemia, Cell, 152, 714, 10.1016/j.cell.2013.01.019 Landau, 2015, Mutations driving CLL and their evolution in progression and relapse, Nature, 526, 525, 10.1038/nature15395 Mullighan, 2008, Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia, Science, 322, 1377, 10.1126/science.1164266 Findlay, 2016, Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy, Nat Commun, 7, 11111, 10.1038/ncomms11111 Aldous, 2018, Personalized neoantigen vaccines: A new approach to cancer immunotherapy, Bioorg Med Chem, 26, 2842, 10.1016/j.bmc.2017.10.021 Boudreau, 2011, Engineering dendritic cells to enhance cancer immunotherapy, Mol Ther, 19, 841, 10.1038/mt.2011.57 Steinman, 2007, Taking dendritic cells into medicine, Nature, 449, 419, 10.1038/nature06175 Peng, 2019, Neoantigen vaccine: an emerging tumor immunotherapy, Mol Cancer, 18, 128, 10.1186/s12943-019-1055-6 Duperret, 2019, A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8(+) T-cell Responses, Impacting Tumor Challenge, Cancer Immunol Res, 7, 174, 10.1158/2326-6066.CIR-18-0283 Ott, 2017, An immunogenic personal neoantigen vaccine for patients with melanoma, Nature, 547, 217, 10.1038/nature22991 Keskin, 2019, Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial, Nature, 565, 234, 10.1038/s41586-018-0792-9 Senzer, 2012, Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer, Mol Ther, 20, 679, 10.1038/mt.2011.269 Barve, 2016, Follow-up of bi-shRNA furin/GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma, Biomed Genet Genomics, 1 Ghisoli, 2015, Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma, Mol Ther, 23, 1103, 10.1038/mt.2015.43 Senzer, 2013, Long Term Follow Up: Phase I Trial of “bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell” Immunotherapy (FANG™) in Advanced Cancer, Journal of Vaccines & Vaccination, 4, 209 Oh, 2016, Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer, Gynecol Oncol, 143, 504, 10.1016/j.ygyno.2016.09.018 Oh, 2020, Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil(R) in frontline maintenance, Gynecol Oncol Rep, 34 Rocconi, 2020, Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial, The Lancet Oncology, 21, 1661, 10.1016/S1470-2045(20)30533-7 Rocconi RP, Stevens EE, Bottsford-Miller JN, et al. Proof of Principle Study of Sequential Combination Atezolizumab and Vigil in Relapsed Ovarian Cancer. Cancer Gene Ther.Submitted. Lou, 2013, High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing, Proc Natl Acad Sci U S A., 110, 19872, 10.1073/pnas.1319590110 Fox, 2014, Accuracy of Next Generation Sequencing Platforms, Next Gener Seq Appl, 1 Kennedy, 2014, Detecting ultralow-frequency mutations by Duplex Sequencing, Nat Protoc, 9, 2586, 10.1038/nprot.2014.170 You, 2020, Detection of genome-wide low-frequency mutations with Paired-End and Complementary Consensus Sequencing (PECC-Seq) revealed end-repair-derived artifacts as residual errors, Arch Toxicol, 94, 3475, 10.1007/s00204-020-02832-0 Craig, 2019, Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells, BMC Cancer, 19, 1081, 10.1186/s12885-019-6313-x Deveson, 2021, Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology, Nat Biotechnol, 10.1038/s41587-021-00857-z Jones, 2021, A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency, Genome Biol, 22, 111, 10.1186/s13059-021-02316-z